PACS Group heads into its August earnings window with an unusual tension: the Street's conviction is building, but the founder is quietly cashing out at the top.
The analyst story is unambiguously bullish — and it moved again this week. UBS analyst A.J. Rice raised his price target to $57 from $50 on July 8, while maintaining a Buy rating. That follows a string of upward revisions since the start of 2026, with Truist Securities, Oppenheimer, and RBC Capital all lifting targets in the wake of what appear to have been strong earnings prints earlier this year. The consensus mean target now sits at $50.83, with PACS trading at $43.62 — implying roughly 16% upside from current levels. The bull case centres on PACS's decentralised model, its real estate purchase-option strategy, and structural tailwinds in post-acute care. Bears point to margin risk at acquired struggling facilities and operational variability inherent in that decentralised approach. One metric that lends the bulls some support: PACS ranks in the 79th percentile on EPS surprise, and 90-day forward EPS momentum sits in the 83rd percentile — the Street has been consistently underestimating this company.
The lending market tells a relaxed story about short positioning. Short interest is modest at 2.8% of the free float — barely above 4.4 million shares — and has edged up just 0.2% on the week. Borrowing costs have eased sharply, down 15% on the week and 42% over the past month to just 0.44%, a level that signals no meaningful demand for new short exposure. Borrow availability is generous at 558% of current short interest, well above the 52-week low of 441%, meaning there are roughly five and a half shares available to lend for every one currently borrowed. The ORTEX short score of 54.8 is middling and has drifted slightly lower over the past week — positioning looks comfortable rather than charged.
Options market participants are slightly more cautious than usual, though not dramatically so. The put/call ratio nudged up to 0.19, about one standard deviation above its 20-day average of 0.16. That is a modest defensive lean — nowhere near the 52-week high of 0.27 — and likely reflects some hedging after a 17.9% monthly rally rather than genuine bearish conviction. The stock pulled back 3.1% on July 7 after gaining 2.3% on the week, consistent with profit-taking after a strong run rather than any fundamental shift.
The more compelling data point this week is insider selling. Founder and Executive Vice Chairman Mark Hancock has sold over $14.5 million of stock across multiple transactions since June 25, offloading shares at prices between $40.30 and $45.33. Chief Accounting Officer Michelle Lewis has also sold across the same period, adding roughly $1.3 million in combined transactions. The 90-day net insider share figure of approximately 1.06 million shares appears positive in isolation, but the recent activity is entirely sales — and Hancock's pace has accelerated as the stock approached the $45 level. He still holds over 34% of the company, so these are portfolio management moves from an enormous position, but the timing into the recent rally is worth noting.
PACS's last two earnings events produced outsized moves: a 29.5% one-day surge in May and a 22.1% jump in a separate event around the same time. With the next print scheduled for August 12, the question worth watching is whether that UBS target upgrade and the momentum in analyst revisions are pricing in execution on the M&A pipeline — or whether Hancock's steady selling at these levels signals his own assessment of near-term fair value.
See the live data behind this article on ORTEX.
Open PACS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
